Dr. Michal Lotem
MD (Doctor of Medicine)
Head, Center for Melanoma & Cancer Immunotherapy
corporate_fareHadassah Medical Center, Jerusalem
Michal Lotem
MD (Doctor of Medicine)
Prof. Michal Lotem, MD, is a medical oncologist and internationally recognised expert in melanoma and cancer immunotherapy at Hadassah Medical Center, Jerusalem. She heads the Center for Melanoma and Cancer Immunotherapy at the Sharett Institute of Oncology and founded the Hadassah Cancer Research Institute. Her work focuses on using the immune system to treat advanced melanoma and other skin-origin cancers.
As a physician-scientist, Prof. Lotem combines direct patient care with translational research in tumour immunology. She trained for around two years in the Surgery Branch of the United States National Cancer Institute under Prof. Steven Rosenberg, a leader in modern cancer immunotherapy and adoptive cell therapy. Her clinical and laboratory work spans immune checkpoint inhibitors, tumour-infiltrating lymphocyte (TIL) therapy, adoptive cell therapy and personalised cancer vaccines. She also leads the CancerRNA research consortium, which explores RNA-based approaches to strengthen anti-cancer immune responses, and her laboratory has published influential work on the SLAMF6 immune receptor in melanoma.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Lotem, subject to hospital availability and case acceptance.
Why Consider Prof. Michal Lotem?
Prof. Lotem brings together advanced melanoma care, immunotherapy expertise and active translational research within one programme.
Areas of Specialisation
Immune-based treatment for melanoma and skin-origin cancers
Prof. Lotem's clinical focus is the immune-based treatment of advanced melanoma and other skin-origin cancers, supported by translational research in tumour immunology.
Melanoma & Skin-Origin Cancers
Diagnosis and immune-based management of advanced and metastatic skin cancers.
- arrow_rightTreatment planning for stage III and stage IV melanoma
- arrow_rightManagement of melanoma that has progressed after prior therapy
- arrow_rightImmune-based evaluation for selected squamous cell and Merkel cell carcinoma
- arrow_rightMultidisciplinary planning for complex skin cancers
Cancer Immunotherapy
Immune checkpoint blockade, combination immunotherapy and vaccine strategies.
- arrow_rightPD-1 and PD-L1 inhibitor therapy for suitable patients
- arrow_rightCTLA-4 inhibitor therapy and combination immunotherapy
- arrow_rightVaccine-based strategies to stimulate anti-tumour immunity
- arrow_rightTranslational research bridging laboratory work and clinical care
Adoptive Cell Therapy
Cellular therapies that use a patient's own immune cells against cancer.
- arrow_rightTumour-infiltrating lymphocyte therapy for selected advanced melanoma
- arrow_rightEligibility assessment based on tumour access, prior treatment and overall health
- arrow_rightLaboratory and translational work on anti-tumour T-cell function, including the SLAMF6 receptor
- arrow_rightStrategies to improve the persistence and activity of anti-tumour T cells
Treatments & Clinical Services
Immune-based cancer treatment approaches
Prof. Lotem's clinical services centre on systemic and cellular immunotherapy for melanoma and selected solid tumours, alongside diagnostic work-up and second-opinion review. Treatment suitability always depends on individual assessment.
Cancer Immunotherapy
Medical OncologyImmune-based systemic treatment for advanced melanoma and selected solid tumours.
Adoptive Cell Therapy
Medical OncologyCellular immunotherapy using the patient's own immune cells, for selected patients.
Diagnostic & Treatment Planning
DiagnosisAssessment and planning before immune-based treatment.
Second Opinion Consultations
Second OpinionIndependent expert review of advanced melanoma and immunotherapy options.
Research & Publications
Translational immunology and peer-reviewed contributions
Prof. Lotem is a physician-scientist whose research focuses on melanoma immunology, adoptive cell therapy and personalised immunotherapy.
A fuller list of Prof. Lotem's publications and research programmes may be available on request through CancerFax.
Education & Training
Prof. Lotem trained in medicine in Israel and completed advanced immunotherapy research training in the United States.
Clinical Experience
Prof. Lotem has built her career at Hadassah Medical Center in Jerusalem, where she leads melanoma and cancer immunotherapy services and research.
Languages & International
Prof. Lotem consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients.
CancerFax can coordinate professional medical interpreter support when required.
How CancerFax Helps You Access Dr. Michal Lotem
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Michal Lotem's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Michal Lotem's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Michal Lotem before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Michal Lotem's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Michal Lotem's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Michal Lotem's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Michal Lotem
Prof. Michal Lotem, MD, is a medical oncologist and cancer immunotherapy specialist at Hadassah Medical Center in Jerusalem, Israel. She heads the Center for Melanoma and Cancer Immunotherapy at the Sharett Institute of Oncology and founded the Hadassah Cancer Research Institute.
Her main focus is the immune-based treatment of advanced and metastatic melanoma and other skin-origin cancers. This includes immune checkpoint inhibitors, tumour-infiltrating lymphocyte (TIL) therapy, adoptive cell therapy and personalised cancer vaccines.
Yes. Prof. Lotem's work is closely associated with the clinical use of tumour-infiltrating lymphocyte (TIL) therapy at Hadassah, an approach available at only a small number of centres worldwide. TIL therapy may be considered for selected patients with advanced melanoma, depending on medical eligibility and institutional protocols.
International patients may seek an opinion at Hadassah Medical Center through the appropriate appointment channels. CancerFax can coordinate medical-report review, case preparation and consultation requests, subject to hospital availability and case acceptance.
Submit your medical reports through CancerFax using the 'Send Your Reports' option. The CancerFax team reviews your pathology, imaging and treatment history, prepares a structured case summary, and coordinates the next steps with the hospital, subject to availability.
The most relevant cancer is melanoma, especially advanced or metastatic melanoma. Her immunotherapy expertise may also be relevant for selected skin cancers and certain immunotherapy-responsive solid tumours, such as some lung and kidney cancers, where immune-based treatment is being considered.
Connect with Michal Lotem Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.